Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib combined with pyrotinib-based first-line treatment for HER2-positive advanced breast cancer
ChiCTR2200058979Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalpiciclib, pyrotinib, fulvestrant and trastuzumab in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058979.